ReviewDiscover oncology2024
Investigating the biomarker value of circRNAs in the diagnosis of colorectal cancer: a systematic review.
Review in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive landscape and future perspectives of exosomal circular RNAs in cardiovascular disease.Frontiers in pharmacology · 2026Review
- Circular RNA-based liquid biopsy: a promising approach for monitoring drug resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) has recently been considered a class of endogenous RNAs that form a continuous closed loop with an ability to cancer development. Due to its properties, circRNAs has promising potential to be considered as non-invasive cancer biomarkers. The present review comprehensively and systematically assessed the role of circRNAs as diagnostic markers in blood or tissue samples of colorectal cancer (CRC) patients. Articles published until September 2022 were searched across Scopus, Web of Science (WoS), and PubMed databases to screen and find suitable circRNAs as diagnostic markers in CRC, Based on inclusion and exclusion criteria, 55 articles were selected as the final included articles. The sample size of the patients group ranged from 12 to 212. Among the circRNAs investigated in this study, 47 circRNAs were increased in patients and probably act as oncogenes and activate the downstream pathways in the initiation and exacerbation of cancer; 28 circRNAs were decreased, which probably acted as tumor suppressors and their decrease played a role in the progression of CRC, indicating that the aberrant expression of circRNAs are involved in the promotion of CRC and may associated with its clinicopathological features. Many pathological processes of cancer are regulated by the altered expression of circRNAs through the regulation of different signaling pathways. According to the results of this study, while circRNAs demonstrates promise as a biomarker for CRC diagnosis, it is necessary to conduct evaluative studies on a larger scale in future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.